Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool helps HIV patients kick the habit

NCT ID NCT03670316

Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a simple tool that helps doctors choose the right stop-smoking medicines for people living with HIV. 371 smokers from three clinics took part. The goal was to see if the tool helped more people quit smoking for at least a week.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

371 people

The number who actually took part.

Started

Aug 2020

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Enrollment in the CNICS clinical cohort. 2. 18 years or older; 3. Receiving HIV care at the UAB, UW or Fenway Health clinics and not anticipating changing clinics over the next six months 4. Smoking greater than or equal to 5 cigarettes per day (cpd) for the past month 5. Living in an unrestricted environment that allows smoking. Exclusion Criteria: 1. Cognitive impairment such that unable to provide informed consent; 2. Non-English speaking; 3. Acutely suicidal, manic, acutely intoxicated, or otherwise not stable enough to provide informed consent; 4. Currently receiving smoking cessation treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIDS HIV Smoking cessation

Contacts and locations

Locations

  • University of Alabama, Birmingham

    Birmingham, Alabama, 35209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.